16TH BIENNIAL

Rivkin Ovarian Cancer Research Symposium

OCTOBER 16-18, 2026 • PHILADELPHIA, PA

PROGRAM

Symposium Co-chairs

Jose Conejo-Garcia, MD, PhD | Duke University
Sophia George, PhD | University of Miami
Gillian Hanley, PhD | University of British Columbia
Kenneth Nephew, PhD | Indiana University
Fiona Simpkins, MD | University of Pennsylvania

FRIDAY, OCTOBER 16

Badge Pickup

12:00 pm – 7:00 pm
Liberty Foyer

Welcome Remarks

3:30 pm – 3:45 pm
Liberty Ballroom AB

3:30 pm **Welcome**
Audra Moran | President and CEO, Ovarian Cancer Research Alliance

3:42 pm **Moment of Silence**
Sophia George, PhD | University of Miami

Opening Keynote

3:45 pm – 4:35 pm
Liberty Ballroom AB

3:45 pm

Keynote Introduction
Gillian Hanley, PhD | University of British Columbia

3:50 pm
Keynote

Decoding Cancer Before It Begins
Ronny Drapkin, MD, PhD | University of Pennsylvania

Patient Advocacy Panel | From Research to Real Life: The Patient Experience of Ovarian Cancer

4:35 pm – 5:40 pm
Liberty Ballroom AB

MODERATOR Tracy Moore, LCSW | Vice President, Support & Education, Ovarian Cancer Research Alliance

PANELIST Angela Desmond, MD, PhD | Survivor

PANELIST Donna Hayden | Survivor

PANELIST Louise Spencer | Caregiver

PANELIST Erin Wright, DNP, MS, BSN, BM, RN, APHN-BC, C-EFM, CMN, FAAN, FACNM | Survivor

PANELIST Kathleen Yeager | Survivor

Break

5:40 pm – 6:10 pm

Session 1: Health Disparities

6:10 pm – 7:00 pm
Liberty Ballroom AB

CO-CHAIR Shailendra Dwivedi, PhD | University of Oklahoma Health Sciences

CO-CHAIR Priyanka Verma, PhD | Washington University School of Medicine in St. Louis

6:10 pm
Invited

Expanding the evidence base: Epidemiologic and molecular insights into ovarian cancer outcomes in Black women
Lauren Peres, PhD, MPH | Moffitt Cancer Center

6:40 pm
Proffered

Contributions of residential social and environmental factors to ovarian cancer survival disparities in Black and White
Francesmary Modugno, PhD | University of Pittsburgh

6:50 pm
Proffered

Race, place, and ovarian cancer mortality: neighborhood deprivation gradients differ by race in Georgia
Lindsay Collin, PhD, MPH | Emory University

OCRA's Research Exchange

7:00 pm – 7:20 pm
Liberty Ballroom AB

Audra Moran | President and CEO, Ovarian Cancer Research Alliance

Matthew Trunnell | Principal Architect, Research Exchange, Ovarian Cancer Research Alliance

Allison Ramiller | Senior Director, Living Lab Registry, Ovarian Cancer Research Alliance

Poster Session #1 & Reception

7:20 pm – 9:00 pm
Liberty Ballroom CD

SATURDAY, OCTOBER 17

Breakfast (provided) & Badge Pickup

7:00 am – 8:00 am
Liberty Foyer

Presentation of OCRA Research Prizes

8:00 am – 8:10 am
Liberty Ballroom AB

Audra Moran | President and CEO | Ovarian Cancer Research Alliance

Session 2: Epidemiology, Population Science, & Survivorship

8:10 am – 9:40 am
Liberty Ballroom AB

CO-CHAIR AnnaJo Smith, MD, MPH | University of Pennsylvania

CO-CHAIR T. Rinda Soong, MD, PhD, MPH | University of Pittsburgh

8:10 am
Invited

Amplifying the patient voice: advocate-informed survey methods to identify unmet needs in ovarian cancer survivors
Rachel Vogel, PhD | University of Minnesota

8:40 am *Invited*

Changing contraception patterns, ovarian cancer risk and implications for the tumor immune microenvironment
Kathryn Terry, ScD | Brigham and Women's Hospital

9:10 am *Proffered*

Pre-diagnosis pain experience, tumor immune profiles, and survival in tubo-ovarian cancer
Naoko Sasamoto, MD, PhD | Fred Hutch Cancer Center

9:20 am *Proffered*

Use of statins and ovarian cancer risk in the Ovarian Cancer Cohort Consortium (OC3)
Britton Trabert, PhD, MS, MSPH | University of Utah

9:30 am *Proffered*

Receipt of germline and somatic testing in ovarian cancer comparing traditional Medicare and Medicare Advantage in NC (P8)
Yeerae Kim, MPH | University of North Carolina at Chapel Hill

Break

9:40 am – 10:00 am

Session 3: Rare Subtypes

10:00 am – 11:00 am
Liberty Ballroom AB

CO-CHAIR Jessica Lang, PhD | University of Wisconsin

CO-CHAIR Dimitrios Nasioudis, MD | University of Pennsylvania

10:00 am *Invited*

Rare and medium rare ovarian cancers: unique needs, challenges and opportunities
David Huntsman, MD, FRCPC, FCCMG | University of British Columbia

10:30 am *Proffered*

Functional drug profiling reveals EGFR therapeutic opportunities in MAPK-wild-type low-grade serous ovarian carcinoma (P16)
Dane Cheasley, PhD | Peter MacCallum Cancer Centre

10:40 am *Proffered*

Combination of XPO1 and MDM2 inhibition is synergistic in TP53 wild-type ovarian cancer
Dimitrios Nasioudis, MD | University of Pennsylvania

10:50 am *Proffered*

IHC-based prognostic substratification of ovarian endometrioid carcinoma
Martin Koebel, MD | University of Calgary

Late Breaking

11:00 am – 11:10 am
Liberty Ballroom AB

CO-CHAIR Jessica Lang, PhD | University of Wisconsin

CO-CHAIR Dimitrios Nasioudis, MD | University of Pennsylvania

11:00 am *Proffered*

Rinatabart sesutecan (Rina-s®) for patients with platinum-resistant ovarian cancer: first efficacy and safety results from the phase 2 cohort of the RAINFOL™-01 study
Elizabeth Lee, MD | Dana-Farber Cancer Institute

Break

11:10 am – 11:30 am

Sponsored Session

11:30 am – 12:00 pm
Liberty Ballroom AB

CO-CHAIR Sophia George, PhD | University of Miami

CO-CHAIR Dmitriy Zamarin, MD, PhD | Mount Sinai

11:30 am *Sponsor*

AbbVie's research and commitment to gynecologic oncology
Valerie Ruslavage and Amber Simon | AbbVie | Presenting Scientific Sponsor

11:40 am *Sponsor*

AstraZeneca Gynecologic Cancer Pipeline Presentation
Kara Glover | AstraZeneca | Advocate Sponsor

11:50 am *Sponsor*

Corcept Clinical Research Overview: Platinum-Resistant Ovarian Cancer & BELLA Study
Zach Whitehead, PharmD | Corcept | Advocate Sponsor

Lunch (provided)

12:00 pm – 1:30 pm
Liberty Foyer

Breakout Discussions A (optional)

12:15 pm – 12:45 pm
Freedom Ballrooms E, F, G, H

DISCUSSION	LEADERS
How to Successfully Collaborate with Pharma/Industry	Emese Zsiros, MD, PhD
Bridging Basic Science Research to the Clinic	David Huntsman, MD, FRCPC, FCCMG
Partnering with Patient Advocates	Gillian Hanley, PhD
Where AI Can Fit Into Your Research	Kathryn Terry, ScD

Breakout Discussions B (optional)

12:45 pm – 1:15 pm
Freedom Ballrooms E, F, G, H

DISCUSSION	LEADERS
Building Clinical and Translational Collaborations	Daniela Matei, MD
Navigating the Current Funding Environment	Goli Samimi, PhD, MPH
DOD Clinical Trials Ovarian Cancer Academy	Sarah Adams, MD and Amanda Fader, MD
DOD Ovarian Cancer Academy	Ronny Drapkin, MD, PhD and Kenneth Nephew, PhD

Session 4: Prevention & Early Detection

1:30 pm – 3:10 pm
Liberty Ballroom AB

CO-CHAIR Alexander Melamed, MD, MPH | Harvard University

CO-CHAIR Achuth Padmanabhan, PhD | University of Maryland

1:30 pm *Invited*
Salpingectomy clinical trials - what have we learned, and where are we going?
Barbara Norquist, MD | University of Washington

2:00 pm *Invited*
Ovarian cancer prevention strategies: pushing boundaries
Ranjit Manchanda, MD, MRCOG, PhD | Queen Mary University of London

2:30 pm *Proffered*
Candidate targets for early HGSC interception and prevention (P36)
Maria Recouvreux, PhD | University of California, Los Angeles

2:40 pm *Proffered*
Biologically-informed polygenic risk prediction and Agentic AI to interpret epithelial ovarian cancer risk variants (P32)
Ping-Hung Lai, MS | Cedars-Sinai Medical Center

2:50 pm *Proffered*
A cross-cohort machine learning classifier for Serous Tubal Intraepithelial Carcinoma (STIC) progression risk
Stephanie Tanis | University of Colorado Anschutz

3:00 pm *Proffered*
CLDN4-targeted iron oxide nanoworms reveal immune-mediated barriers to tumor-specific delivery in HGSC (P26)
David Angarita, MSPS | University of Colorado Anschutz

Break

3:10 pm – 3:30 pm

Session 5: New Therapeutic Approaches

Sponsored by AbbVie

3:30 pm – 5:20 pm
Liberty Ballroom AB

CO-CHAIR Lindsay Brubaker, MD | University of Colorado

CO-CHAIR Rebecca Porter, MD, PhD | Harvard University

3:30 pm *Invited*
Where are we now, what is on the therapeutic horizon for ovarian cancers?
Elise Kohn, MD | National Cancer Institute

4:00 pm *Proffered*
Multimodal profiling guides personalized therapy in ovarian cancer: from TuPro to OV-Precision (P78)
Francis Jacob, PhD | University Hospital Basel and University of Basel

4:10 pm *Proffered*
Large-scale drug screening uncovers actionable therapeutic dependencies across molecular subtypes of LGSOC
Kathleen Pishas, PhD | Peter MacCallum Cancer Centre

4:20 pm *Proffered*
MDM2 inhibition and degradation reactivate p53 in TP53-wildtype ovarian cancer (P60)
Ann Cathcart, MD, PhD | University of Pennsylvania

4:30 pm *Proffered*
Targeting MAT2A attenuates DNA damage response and cancer stemness to improve platinum sensitivity in ovarian cancer (P112)
Shu Zhang | Indiana University

4:40 pm *Proffered*
Relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer: phase 3 ROSELLA final overall survival results (P110)
Oladapo Yeku, MD, PhD, FACP, FASCO | Mass General Brigham Cancer Institute

4:50 pm *Proffered*
Doublecortin-like kinase 1 (DCLK1) CAR T cells demonstrate durable efficacy against chemoresistant HGSOC (P72)
Ameera Hasan, MBBS, PhD | University of Oklahoma Health

5:00 pm *Proffered*
Intraperitoneal administration of IL-12 mRNA LNPs confers lasting tumor reduction through ascitic immune reprogramming (P94)
Amanda Murray, MS | University of Pennsylvania

5:10 pm *Proffered*
Activating tumor-infiltrating immune cells to enhance anti-tumor immunity in metastatic ovarian cancer models (P62)
Yifan Chang, MD | University of California, San Francisco

Poster Session #2 & Reception

Sponsored by AbbVie

5:20 pm – 7:00 pm
Liberty Ballroom CD

SUNDAY, OCTOBER 18

Breakfast (provided) & Badge Pickup

7:00 am – 8:00 am
Liberty Foyer

Session 6: Immuno-oncology

8:00 am – 9:50 am
Liberty Ballroom AB

CO-CHAIR Laura Chambers, DO | Ohio State University

CO-CHAIR Denarda Dangaj, PhD | Ludwig Cancer Research

8:00 am *Invited*
Linking transcriptomic biomarkers with tumor microenvironmental conditions in an ovarian cancer clinical trial
Sarah Adams, MD | University of New Mexico

8:20 am *Invited*
Drivers of immune heterogeneity in ovarian cancer
Dmitriy Zamarin, MD, PhD | Mount Sinai

8:40 am *Invited*
From Rare to Routine: Engineering Durable Immune Responses in Ovarian Cancer
Emese Zsiros, MD, PhD | Roswell Park Comprehensive Cancer Center

9:00 am *Proffered*
Understanding T cell senescence to optimize ovarian cancer immunotherapy (P126)
Flavia De Carlo, MSc, PhD | Ludwig Cancer Research Center at the University of Lausanne

9:10 am *Proffered*
GB-5267, a MUC16-targeted, IL-18-armored CAR T-cell therapy for platinum-resistant ovarian cancer: trial-in-progress (P128)
Celia DeJohn, PhD | Roswell Park Comprehensive Cancer Center

9:20 am *Proffered*
Chronic type I interferon exposure in ovarian cancer-associated ascites mediates natural killer (NK) cell dysfunction (P120)
Grace Birch, PhD | Dana-Farber Cancer Institute

9:30 am *Proffered*	**Targeting B cell checkpoint CD22 in high grade serous ovarian cancer (P150)** Ramya Parameswaran, MD, PhD I University of California, San Francisco
9:40 am *Proffered*	**Spatial transcriptomic mapping of fallopian tube precursor lesions (P154)** Kathleen Trang I University of Maryland

Break

9:50 am – 10:10 am

Session 7: Overcoming Drug Resistance

10:10 am – 11:50 am
Liberty Ballroom AB

CO-CHAIR	Elizabeth Christie, PhD I Peter MacCallum Cancer Centre
CO-CHAIR	Elizabeth Stover, MD, PhD I Harvard University

10:10 am *Invited*	**Unleashing Cell Cycle Checkpoints to exploit Cyclin E1 amplification in Platinum Resistant Ovarian Cancers** Fiona Simpkins, MD I University of Pennsylvania
10:40 am *Invited*	**The Chemotherapy Conundrum** Benjamin Bitler, PhD I University of Colorado Anschutz
11:10 am *Proffered*	**Investigating heterogeneity and resistance in end-stage HGSOC** Elizabeth Christie, PhD I Peter MacCallum Cancer Centre
11:20 am *Proffered*	**PARP-targeted theranostic approach to overcome PARPi resistant ovarian cancer (P166)** Sarah Gitto, PhD I University of Pennsylvania
11:30 am *Proffered*	**Locus-specific RAD51 loading by MRG15-PALB2 preserves TMEJ dependence** John Krais, PhD I Washington University
11:40 am *Proffered*	**PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer** Jie Hao, MD, PhD I Dana-Farber Cancer Institute

Break

11:50 am – 12:10 pm

Closing Keynote

12:10 pm – 12:58 pm
Liberty Ballroom AB

12:10 pm

Keynote Introduction

Jose Conejo-Garcia, MD, PhD | Duke University

12:12 pm
Keynote

Metabolic Adaptation and Targets in Platinum Resistant Ovarian Cancer

Daniela Matei, MD | Houston Methodist Neal Cancer Center

12:58 pm

Closing Remarks

Kenneth Nephew, PhD | Indiana University